Xocova belongs to the same class of drugs as Pfizer’s Paxlovid and Merck’s Lagevrio, which are used to help prevent severe cases of COVID-19. More on Shionogi & Co. Shionogi & Co. reports H1 ...

Japan has approved the Shionogi's antiviral therapy, Xocova, for COVID-19 on an emergency basis. The government has also purchased 1 million doses initially, estimated to be worth $2.5 billion USD.

Shionogi’s did just that. Reshma Ramachandran, a family physician at Yale, told me that if the early Xocova results hold up in additional trials, she’d be inclined to prescribe it to her ...

Xocova is an approved-in-Japan COVID antiviral. Other COVID investments are causing valuations to fall as their opportunities subside. However, this allows Shionogi to be the next great COVID ...

Shionogi recently presented results from the ... About ensitrelvir Ensitrelvir (known in Japan as Xocova ®), an oral antiviral drug for COVID-19, is currently approved under the emergency ...

Shionogi & Co.’s experimental Covid-19 treatment Xocova failed to win the backing of health experts in Japan who said there wasn’t enough data to show the medicine’s efficacy. The panel ...

Outside Japan, Xocova is also approved in Singapore. Sanofi keeps Novavax afloat with $1.2B bet on its vaccine platform Despite the misfire in SCORPIO-HR, Shionogi said that a pre-defined ...

While Xocova came later to the market than Shionogi initially hoped for after Japanese regulators twice requested more data, the company says interim results of a study suggest taking the pill ...

Ensitrelvir, known commercially as Xocova, showed a statistically significant reduction in participants with symptomatic infection after exposure to household contacts with COVID, Shionogi said in ...

Shionogi’s COVID-19 treatment Xocova was found to reduce the risk of developing at least one of the symptoms of long COVID-19, the Osaka-based pharmaceutical company said Wednesday. Shionogi ...

Shionogi & Co.’s Covid pill could be approved ... The Japanese drugmaker has been submitting data to regulators in China and expects Xocova to be authorized for use as early as this quarter ...

TOKYO, May 13 (Reuters) - Japan's Shionogi & Co (4507.T), opens new tab said on Monday its pill-based treatment for COVID-19 did not meet the primary endpoint of showing a statistically ...